HaemoneticsHAE
Recorded

Haemonetics 2027 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2027Duration52 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to Haemonetics Corporation Second Quarter 2027 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to turn the call over to Olga Guyette.

Olga GuyetteVP of Investor Relations and Treasury

You may begin. Good morning, and thank you for joining us for Haemonetics Second Quarter Fiscal Year 2027 Conference Call and Webcast.

Olga GuyetteVP of Investor Relations and Treasury

I am joined today by Chris Simon, our CEO, and James D'Arecca, our CFO. This morning, we reported second quarter and first half fiscal 2027 results and updated our fiscal 2027 guidance. Our earnings release, supplemental presentation, and related materials are available in the Investor Relations section of our website. Before we begin, I would like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of FX, the exit of certain liquid solution products, and our fiscal year 2027 guidance is also adjusted for the impact of the 53rd week. We will also refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items.

Olga GuyetteVP of Investor Relations and Treasury

A full list of excluded items, reconciliations to our GAAP results, and comparisons with the prior year periods are provided in our earnings release. Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's earnings release and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements. Now, I would like to turn it over to Chris.

Chris SimonCEO

Good morning, everyone. Thank you for joining us. We delivered a strong quarter and first half with growth across plasma, Blood Management, and Interventional Technologies. Organic revenue growth was 10% in the second quarter and 8% in the first half, and adjusted earnings per share was $1.35 in the quarter and $2.49 in the first half, growing 6% in both periods. Beyond these strong results, we reached several important milestones that position us for future growth. We expanded our CSL relationship, secured key regulatory approvals, and launched innovative MedSurg products. These achievements reflect years of investment in our technology, our customer relationships, and our execution. Let us discuss our business results. MedSurg delivered a solid quarter of broad-based growth, increasing 6% organically in both the second quarter and first half. Blood Management Technologies grew 7% organically in the quarter and 8% in the first half.

Chris SimonCEO

Within BMT, hemostasis management growth was driven by greater account penetration, higher TEG utilization, and continued share gains. The TEG 5000 capital upgrade cycle is winding down, but durable growth is being driven by mid-teens recurring TEG 6s disposables growth. Transfusion management revenue grew well into the double digits in both periods, becoming an increasingly meaningful contributor to the franchise. With our evolving portfolio, we are building our high-margin recurring revenue base while giving customers greater flexibility to adopt integrated software solutions that improve workflow automation, transfusion safety, and traceability. This growth was partially offset by cell salvage. Interventional Technologies grew 3% organically in both the second quarter and first half, sustaining the return to growth established in Q1. Vascular closure led performance, with VASCADE MVP and VASCADE MVP XL growing in the low double digits in electrophysiology in both periods.

Chris SimonCEO

Strong demand and improved commercial execution are driving greater utilization and share gains as the underlying market stabilizes. Vascular closure momentum was partially offset by a challenging prior year comparison in esophageal cooling. We also advanced our growth strategy through several important milestones. We extended VASCADE MVP XL globally, with initial CE Mark certification and Japanese regulatory approval for the expanded indication. We launched the PacePro guidewire, broadening our structural heart guidewire portfolio with a solution designed to improve procedural efficiency within familiar physician workflows. We received U.S. FDA approval for PerQseal Elite, extending our vascular closure offering into large-bore structural heart and endovascular procedures. While these initiatives are not expected to materially contribute to FY 2027 revenue, they leverage our existing commercial infrastructure to broaden our market reach and strengthen our runway for sustained long-term growth.

Chris SimonCEO

Strong first-half execution, improving momentum in Interventional Technologies, and new product launches reinforce our confidence in the business's growth trajectory and significant long-term opportunity. However, we remain disciplined in our outlook, relying on demonstrated progress to inform our guidance. Therefore, we are reaffirming our fiscal 2027 MedSurg organic revenue growth guidance of mid-single digits. Turning to apheresis, organic revenue grew 14% in the second quarter and 10% in the first half. Within that, plasma grew 18% and 13% respectively, driven by prior share gains, strong underlying collections, and the rollout of Persona PLUS. Second quarter global plasma collections grew in the high single digits. Continuous long-term investment in our technology and our service delivery has helped us to gain share and accelerate adoption of our integrated platform. Persona PLUS strengthens our offering by increasing plasma yield, improving center productivity, and lowering customers' cost per liter.

Chris SimonCEO

The rollout is on schedule with substantial adoption across our customer base. Our expanded CSL relationship further validates the superiority of our value proposition. We are scaling capacity to supply CSL while supporting continued strong demand across our customer base. We anticipate completing the rollout of NexSys PCS with Persona PLUS to all of CSL's U.S. plasma centers before the end of calendar 2027. Continued Persona PLUS adoption and additional share gains create multi-year durable growth with benefits extending beyond the initial implementations. We remain committed to advancing our technological advantage by investing in new capabilities that improve customer economics and the donor experience. Other apheresis was flat in the quarter and down modestly in the first half, as strength in red cell collection was offset by order timing and continued portfolio rationalization.

Chris SimonCEO

We are raising fiscal 2027 apheresis organic revenue growth guidance to high single digits from low to mid-single digits, reflecting stronger first-half performance, Persona PLUS adoption, and formally confirmed CSL center conversions through Q3, partially offset by a modest decline in other apheresis. Consistent with our prior outlook, we have not factored in any incremental revenue contribution from second-half plasma collections growth, and we expect our second-half growth to be weighted towards Q4, reflecting certain contractual economics. We anticipate additional CSL share in our fourth quarter. However, we will wait until specific rollout plans are confirmed to incorporate that into our guidance. Our total company revenue first-half results and greater visibility into customer commitments across our business support an increase in our fiscal 2027 revenue outlook.

Chris SimonCEO

We now expect organic growth of 6%-9%, up from 4%-7%, and reported growth of 8%-11%, up from 5%-8%. We enter the second half with multiple catalysts for PAL revenue growth ahead of our markets and the potential to accelerate earnings growth as we capture these opportunities. We are focused on executing customer conversions, advancing new product adoption, and scaling to meet growing demand. We are turning durable growth into lasting value.

James D'AreccaCFO

Over to you, James. Thank you, Chris, and good morning, everyone.

James D'AreccaCFO

The momentum Chris described is increasingly evident in our financial performance. Favorable portfolio mix, growing recurring revenue, and strong cash generation reinforce the quality of our business model. With multiple growth catalysts ahead, we see a compelling opportunity to turn sustained revenue growth into stronger earnings power over time. Starting with profitability, second quarter adjusted gross margin increased approximately 140 basis points year-over-year to 61.9%. This included a roughly 200 basis point benefit from tariff refunds, partially offset by a 60 basis point foreign exchange headwind. Excluding these two factors, gross margin was essentially flat, as a more favorable portfolio mix, coupled with recent innovation, offset higher manufacturing and supply chain costs. For the first half, adjusted gross margin increased approximately 60 basis points to 61.2%.

James D'AreccaCFO

Favorable portfolio mix and the second quarter tariff refund more than offset additional inflationary pressures and the margin impact of prior year software licensing revenue. Second quarter adjusted operating expenses increased 15% to $127.6 million, and first half expenses increased 11% to $253.2 million. Three factors drove the increase. First, investments to capture future growth, including Vivasure, commercial readiness for new product launches and regulatory approvals, combined with higher research and development costs as we continue to strengthen our technology. Second, higher personnel-related expenses, including self-insured medical claims and performance-based compensation, reflecting significant outperformance against our original annual plan. Finally, higher freight expense, driven by increased volumes, higher fuel prices, and expedited shipments as we prioritize supply readiness to meet strong demand for our products.

James D'AreccaCFO

Adjusted operating margin was 26.3% in the quarter, down 40 basis points year-over-year, and 24.9% for the first half, down 50 basis points. For fiscal 2027, we now expect adjusted operating margin expansion of 0 to 50 basis points, compared with 50 to 100 basis points previously. This reflects investments ahead of plasma share gains, higher performance-based compensation, and continued cost pressures. Our priority is to build the capacity and supply reliability needed to execute the CSL rollout while serving strong demand across our customer base. We are committing manufacturing and distribution resources before the associated volumes fully materialize. As volumes scale and logistics become more efficient, we expect the near-term costs to moderate, supporting stronger operating leverage. Our adjusted effective tax rate was 24.7% in the second quarter, generally consistent with the prior year period. The first half rate was 25.2% compared with 24.8% last year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day